Company: ASLAN Pharmaceuticals Limited
Symbol: ASLN
Description: They are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Shares: 7.5 million ADSs
Price Range: $8.05-$8.05
Trade Date: 5/3
Underwriter(s): Leerink Partners, Piper Jaffray
Co-Manager: BTIG, H.C. Wainwright & Co., CLSA
Terms Added: 4-16-18
Note: Their ordinary shares are currently listed on the Taipei Exchange, or TPEx.
Business:
Their Asia development platform is designed to enable them to accelerate the development of drugs to treat these diseases. Their portfolio is comprised of four product candidates which target: validated growth pathways applied to new patient segments; novel immune checkpoints; and novel cancer metabolic pathways.
Their lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer for which they expect to report topline data in 2019. They are also conducting a global Phase 2/3 clinical trial of varlitinib for gastric cancer for which they expect to report topline Phase 2 data in the second half of 2018.
They focus on cancers, such as gastric cancer and biliary tract cancer, which are orphan diseases in the United States and Europe for which there are few, if any, approved therapies.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish